Lambda snags Biovail's Toronto CRO

India's Lambda Therapeutic Research has acquired Biovail's Canadian CRO and renamed it Lambda Canada. The 46,000-square-foot research center in Toronto houses 194 beds and a Phase I first-in-human operation. Lambda says it wants to burnish its reputation for developers interested in developing new therapies for the U.S. market. Report

Suggested Articles

The deal comes almost two years after Roche dropped the tumor microenvironment modulator after putting it through a clutch of early-phase studies.

The buzzy life sciences company Verily is looking to speed up COVID testing with a new lab based at its native South San Francisco.

Although Genfit canned its NASH program last month, it has been plugging away at a blood-based diagnostic for the liver disease.